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PROTOKOL MUDAH BIOASAI IN VITRO TERHADAP SEL 
MIKOBAKTERIA FASA PENDAM 
 
ABSTRAK 
 
 Pembangunan ubat-ubatan baru terhadap tuberkulosis (TB) terencat 
disebabkan oleh kompleksiti protokol makmal asai pendam in vitro. Oleh itu, tujuan 
utama kajian ini adalah untuk menambahbaik protokol TB pendam yang mudah 
dengan memanipulasi parameter-parameter pertumbuhan biasa dengan 
menggunakan empat spesies Mycobacterium tumpang, iaitu M. smegmatis,              
M. fortuitum, M. kansasii, and M. tuberculosis H37Ra. Pengoptimuman 
pertumbuhan fasa awal dengan memanipulasi ketersediaan nutrien, keadaan 
pengeraman, kandungan O2, dan pengudaraan sistem kultur telah dijalankan dalam 
sistem kultur kelompok selama 10 - 12 hari. Hasil kajian menunjukkan bahawa 
penambahan 10% suplemen pengayaan dalam sistem kultur yang statik pada 
persekitaran sub-anaerobik 4% CO2, dan kandungan O2 sebanyak 0.25 nisbah 
“headspace” menyebabkan sel mikobakteria memasuki fasa pertumbuhan pendam. 
Manipulasi pertumbuhan ini juga melanjutkan tempoh fasa pendam kepada 5 - 6 hari 
berbanding dengan sel kawalan yang menjalani pertumbuhan normal. Replikasi 
parameter yang telah dioptimumkan dalam sistem piring mikro 96-perigi untuk 
digunakan dalam asai pelbagai sampel, didapati berupaya menghasilkan tempoh fasa 
pendam yang lebih panjang. Penilaian kadar metabolisme sel-sel fasa pendam yang 
diukur melalui paras adenosina 5’-trifosfat dengan menggunakan asai luciferase 
biopendarkilau telah menunjukkan penurunan dalam nilai-nilai pendarkilau sebanyak 
1.6 – 2.3 kali ganda berbanding spesies Mycobacterium dalam fasa log. Pemerhatian 
xviii 
 
morfologi struktur luar sel pendam di bawah mikroskop elektron imbasan 
menunjukkan bahawa sel ini dalam keadaan sihat dan utuh tanpa pembentukan septat. 
Ini menunjukkan bahawa mereka masih hidup tetapi tidak menjalani replikasi aktif. 
Akhir sekali, protokol untuk aktiviti terhadap mikobakteria fasa pendam telah 
ditambahbaik dengan menyesuaikan prosedur asai kolorimetri piring mikro dengan 
menggunakan tetrazolium bromida sebagai reagen redoks. Protokol ini diuji dengan 
menggunakan drug TB yang telah diketahui. Aktiviti sel pendam ini dinilai 
berdasarkan nilai kepekatan perencatan minimum drug itu dan dibandingkan dengan 
aktiviti sel fasa log. Protokol baru yang dihasilkan untuk mengukur kerentanan drug 
terhadap spesies Mycobacterium pendam telah berjaya ke tahap tertentu, yang boleh 
dilihat dari segi perbezaan nilai MIC antara fasa log dan pendam M. smegmatis dan 
M. fortuitum. Walau bagaimanapun, protokol itu tidak menunjukkan aktiviti yang 
sama terhadap M. tuberculosis H37Ra pendam. Ini mencadangkan penambahbaikan 
protokol asai ini masih diperlukan. Kesimpulannya, hasil kajian ini menunjukkan 
bahawa parameter pertumbuhan normal pada kadar yang sesuai memang boleh 
mendorong sel mikobakteria memasuki fasa pertumbuhan pendam yang lebih 
panjang. Oleh itu, dengan menggunakan simulasi ini, suatu protokol makmal yang 
mudah dapat dikembangkan untuk menyukat aktiviti ejen berpotensi terhadap TB 
pendam. 
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A SIMPLE IN VITRO BIOASSAY PROTOCOL AGAINST LATENT 
MYCOBACTERIAL CELLS 
 
ABSTRACT 
 
Development of new drugs against latent tuberculosis (TB) is partly hindered 
by the complexity of laboratory protocol for dormant in vitro assay. Therefore, the 
main aim of this study was to improvise a simple protocol for latent TB by 
manipulating normal growth parameters using four surrogate Mycobacterium species:                   
M. smegmatis, M. fortuitum, M. kansasii, and M. tuberculosis H37Ra. Initial growth 
optimizations by manipulating nutrient availability, incubation condition, O2 content, 
and aeration of the culture system were carried out in a batch-culture system over   
10 - 12 days. The results showed that an addition of 10 % enrichment supplement in 
combination with a static culture system in sub-anaerobic environment of 4 % CO2, 
and an O2 content of 0.25 headspace ratio induced the mycobacterial cells to enter 
latent phase of growth. These growth manipulations also extended the duration of 
latent phase to 5 - 6 days compared to the control cells undergoing normal growth. 
Replication of the optimized parameters in a 96-well microplate system for use in the 
assay of multiple samples produced longer duration of latent phase. Assessment of 
the metabolic rate of the latent phase cells by measuring the adenosine 5’-
triphosphate levels using luciferase bioluminescence assay showed a decline in 
luminescence values of 1.6 – 2.3 folds compared to the log phase of the 
Mycobacterium species. Observation of the external structural morphology of these 
dormant cells under a scanning electron microscope showed that these cells were 
healthy and intact but lacked septate formation, indicating that they were alive but 
xx 
 
not undergoing active replication. Finally, the protocol for activity against latent 
phase mycobacteria was improvised by adapting the procedure of colorimetric 
microplate assay using tetrazolium bromide as a redox reagent. The protocols were 
tested using known TB drugs. The results based on minimum inhibitory 
concentration (MIC) values of the drugs were compared to their activity against log 
phase cells. The newly established protocol for measuring drug susceptibility against 
dormant Mycobacterium species were successful to a certain extent, which can be 
seen by the difference in MIC value between log and latent phase culture of             
M. smegmatis and M. fortuitum. However, the protocol did not correspond well 
against dormant M. tuberculosis H37Ra, suggesting further improvement of the 
assay protocol is still required. In conclusion, the findings in this study showed that 
normal growth parameters at the right proportion could indeed induce mycobacterial 
cells to enter a longer latent phase of growth and using such simulation, it is possible 
to develop a simple laboratory protocol to test the activity of potential agents against 
latent TB.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 INTRODUCTION 
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) was 
first discovered by Robert Koch in 1882. It accounts for a major cause of morbidity 
and mortality among infectious diseases (Dye et al., 1999). According to the World 
Health Organization (WHO, 2015b), one third of the world’s population is infected 
with TB. In 2014, 9.6 million new TB cases were reported with 1.1 million deaths 
(WHO, 2015b). The standard treatment regimen for TB requires a combination of 
three to four drugs over a long period of six to nine months (WHO, 2010). The 
emergence of multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB 
(XDR-TB) strains further complicate the TB management leading to more incidence 
cases and number of deaths. The global TB burden worsens even more as the human 
immunodeficiency virus (HIV) is known to fuel the epidemic of TB (Zhang et al., 
1994). In addition, the increasing occurrence of latent or dormant TB, whereby the 
TB bacilli are able to survive inside the host’s primary immune cells under stress 
conditions, makes the treatment goal even more difficult to achieve (Gupta & Bhakta, 
2012).   
Various in vivo and in vitro models have been proposed to study latent TB 
(Tufariello et al., 2003). The best animal model would be the model that could 
contain very small amount of TB bacteria in it for years while maintaining its latent 
phase, in which, sudden reactivation is infrequent and could be reactivated when 
immunodeficiency occurs (Tufariello et al., 2003). However, in vivo models such as 
mice, have proven to be difficult because the immune response does not reflect a 
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latent infection in human (Tufariello et al., 2003). Mice models are also quite 
resistant towards development of TB as they could control the infection with strong 
but stable tissue burdens in themselves (Orme & Collins, 1994). Another example of 
animal model, guinea pig, had failed to establish a prolonged latent state of TB 
although these animals are highly susceptible to TB infection (Wiegeshaus et al., 
1989). In addition to the above disadvantages, animal models are less affordable in 
comparison to the usage of in vitro models such as growth in liquid and on solid 
media. Current in vitro models such as hypoxia and nutrient starvation models had 
also failed to give an exact simulation of TB infection in the lungs, but they are 
comparatively affordable (Betts et al., 2002). In these models, many physiologic 
assays are involved in order to maintain the dormant state, in addition to labourious 
procedures and the dangerous handling of the slow-growing and highly pathogenic 
M. tuberculosis (Wayne & Hayes, 1996). These limitations further increase the 
urgency to establish new in vitro models, which should be simpler, faster, and safer. 
Therefore, this study was concerned with establishing a simple bioassay protocol 
using an in vitro growth model by utilizing simple laboratory manipulations with 
four different surrogate Mycobacterium species. Variables including nutrient 
contents, oxygen (O2)/carbon dioxide (CO2) availability, temperature and pH were 
used to induce latent TB with minimal metabolic rate. 
 
1.1 AIM AND OBJECTIVES 
The main aim of this research was to simulate latent tuberculosis (TB) phase 
utilizing simple in vitro bioassay protocols using four Mycobacterium species, 
namely, M. smegmatis, M. fortuitum, M. kansasii and M. tuberculosis H37Ra. These 
species were selected as the test organisms because they are common surrogate 
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organisms of the highly pathogenic etiologic agent of TB, M. tuberculosis. Since 
they are not pathogenic, the research can be carried out in a normal Risk Level 2 
laboratory. The specific objectives were: 
1. To determine the parameters that will cause M. smegmatis, M. fortuitum,         
M. kansasii and M. tuberculosis H37Ra to enter latent phase using simple 
laboratory manipulations. 
2. To develop laboratory procedures for maintaining latent growth phase in 96-
well microplate. 
3. To determine the correlation of growth rate and metabolic rate in latent phase. 
4. To evaluate the latent bioassay protocol using known drugs. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 DEFINITION OF TERMINOLOGIES 
A few terminologies are used in this thesis to describe the characteristics of 
the tuberculosis (TB) disease, mycobacterial cells and the phases in their growth 
cycle. These terminologies are as follows: latent TB disease, lag phase, log phase, 
stationary phase, dormant bacterial cells, and latent phase. Latent TB disease is 
defined as a condition, in which an individual is infected with Mycobacterium 
tuberculosis, but does not exhibit any signs or symptoms of active TB disease 
(Hauck et al., 2009). Lag phase of microbial growth is defined as the period between 
inoculation of bacterial culture and the time of the commencement of its maximum 
rate of growth (Black, 2008). Log phase of microbial growth is the exponential phase 
of growth of a microorganism (Zwietering et al., 1990). Stationary phase is defined 
as the period when the number of bacterial cells stops increasing, whereby the rate of 
cell death is equivalent to the rate of cell growth (Zwietering et al., 1990; Kolter et 
al., 1993). Dormant bacterial cells are those that are in an inactive condition where 
their growth and metabolic processes are halted (Biology Online Dictionary, 2005). 
Latent phase cells are those being in condition of biological rest or inactivity 
characterized by cessation of growth or development and the suspension of many 
metabolic processes (English-Spanish Dictionary, 2012). The latent mycobacterial 
cells are actually in the state of stationary phase whereby they remain dormant in the 
host tissues (Flynn & Chan, 2001). In this thesis, these mycobacterial cells are 
referred to as latent phase cells for easy description. 
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2.2 TUBERCULOSIS 
2.2.1 Overview 
Human beings have been plagued with TB for thousands of years         
(Daniel et al., 1994). The seriousness of this epidemic is proven when WHO 
declared TB as a global health emergency in 1993 (WHO, 2002). Until today, it is 
still the single top infectious disease, which causes more death in humans, despite 
the extensive control measures that had been carried out since decades ago     
(Wayne, 1994).  
There are three types of TB, namely, pulmonary (PTB), extra-pulmonary 
(EPTB) and latent TB (Dugdale, 2011). PTB is the most common type of TB disease. 
As M. tuberculosis can float in the air and stay there for several hours, an individual 
will get infected if he or she inhaled the droplets expelled from an infected individual. 
Symptoms of PTB include coughing, fever, excessive sweating, weight loss and 
fatigue. Individuals with PTB will be required to stay home and avoid close contacts 
with others until they are no longer contagious (Dugdale, 2011). TB can also be 
classified into primary and post-primary forms. Primary TB patients are patients that 
are not previously exposed to M. tuberuculosis infection (American Thoracic Society 
and Centers for Disease Control and Prevention (ATSCDCP), 2000). It is more 
commonly found in infants and children. On the other hand, post-primary TB usually 
occurs after one to two years prior to initial infection. Reactivation of these tubercle 
bacteria is usually associated with a weak immune system (ATSCDCP, 2000). 
EPTB is not as common as PTB (Lee, 2015). In EPTB, TB infection occurs 
in various organs such as lymph node, bones and other organs than lungs. 
Diagnosing EPTB is extremely hard, as clinical samples obtained from relatively 
inaccessible sites might be paucibacillary, which might affect the sensitivity of 
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diagnostic tests. This is important as the conclusive diagnosis of TB is to isolate      
M. tuberculosis by culture from patients’ samples (Lee, 2015). 
 Unlike PTB, latent TB infection does not show any evidence of clinical 
symptoms as manifested by active TB (Mack et al, 2009). M. tuberculosis antigens 
do not stimulate an immune response in the body, but instead remain dormant  
(Mack et al, 2009). Patients with latent TB infection usually converts to active TB 
disease within five years after infection.  Latent TB patients are not infectious as 
long as the mycobacteria is not activated (Comstock et al, 1974). 
TB is actually a disease that can be cured and prevented. In fact, TB case 
rates have shown gradual decrease in many parts of the world (WHO, 2015b). 
However, limitation of available resources, disruption of societal activities and the 
dispersion of HIV epidemic have hindered preventive and treatment measures and 
thus, fuelled the increase of local and regional TB cases (Frothingham et al., 2005).  
 
2.2.2 Epidemiology of tuberculosis 
In 2013, it was estimated that nine million people were infected with TB with 
1.5 million deaths. Out of these total number, around 360,000 individuals were 
patients with acquired immunodeficiency syndrome (AIDS) (Baddeley et al., 2014). 
The global number of cases of new and relapse TB were about 6.1 million in 2014 
(WHO, 2015b). It was estimated that there were 133 TB infection per 100, 000 
people worldwide. Geographically, the Asian and African regions account for the 
highest rate of TB incidences and deaths per capita (Figure 2.1). The rate of TB 
mortality in South East Asia also shows a worrying figure, killing 24 per 100, 000 
population (WHO, 2015b). 
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HIV patients, due to their weak and compromised immune system, are 26 
times more likely to develop TB disease compared to HIV negative individuals 
(WHO, 2015b). Although the number of death caused by HIV-associated TB shows 
a 32 % decline over 10 years, TB death among HIV patients still contributes for    
25 % of all TB death worldwide. This shows that HIV-associated TB still remains as 
an enormous burden of preventable death and ill-health (WHO, 2015b).  
 
Figure 2.1. Global incidence of tuberculosis, 2014. 
(WHO, 2015b) 
 
Statistics show that TB infection in Malaysia is slightly better compared to its 
neighbouring countries. According to the Malaysian TB dataset, HIV positive 
associated TB cases in Malaysia is only 2.1 %, which is much lower than most 
countries around the globe (Malaysia Health Management and Disease Control, 
2012).  The number of new and relapse TB cases in 2014 was 24,054 cases          
(103 per 100, 000 people), which is also slightly lower than the global figure       
(133 per 100,000 population) (WHO, 2015b). Mortality rate of HIV negative TB 
patients in Malaysia is 8 %, which is also much lower than the global figure (16 %).  
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Although recent statistical data shows a slight hope in future eradication of 
TB, however, the percentage of newly arisen MDR-TB cases from treated TB 
patients had increased to 20.5 % in year 2013 (Baddeley et al., 2014). Twelve 
percent of newly recorded TB cases globally are found to be MDR-TB patients 
(Figure 2.2). The figure is even higher in Malaysia, which is 37 % of all local 
recorded cases (WHO, 2015b). MDR-TB is very dangerous as the treatment success 
rate is only 37 % compared to 88 % for pulmonary TB (WHO, 2015b). Hence, 
immediate actions and measures need to be taken to prevent the continuous rise of 
TB patients on the global scale. 
 
Figure 2.2. Global incidence of multiple drug-resistant tuberculosis, 2014. 
(WHO, 2015b) 
2.2.3 The tubercle bacteria 
Mycobacterium tuberculosis, the etiologic agent of TB is an intracellular 
pathogen that appears as long and straight rod-shaped cell (Falkinham, 2002; 
Tufariello et al., 2003). The mycobacterial cells could not form any capsules, flagella,  
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Figure 2.3.  Schematic representation of the mycobacterial cell wall. 
(Quesnaiux et al., 2004) 
 
 
 
 
 
Figure 2.4. Acid-fast stain of Mycobacterium tuberculosis. 
(Kubica, 1979) 
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exotoxins or spores but have a waxy cell wall, which is made up of mycolic acid 
(Figure 2.3) (Colijn et al., 2009). M. tuberculosis exhibits cord factors from in vitro-
grown colonies, which are also known to cause the mycobacteria to form long 
strands of cells (Talaro & Chess, 2011; Todar, 2011). These characteristics 
contribute to the acid-fastness property (Figure 2.4) of the cells and cause an increase 
in virulence by preventing killing by lysosome of the macrophages (Hunter et al., 
2006). Acid-fast bacteria are impermeable to certain dye and stains. However, they 
cannot be decolorized by heating or treatment with acidified organic compounds 
once they are being stained (Todar, 2011). Mycobacterial cell wall consists of an 
inner layer and outer layer (Hett & Rubin, 2008). The inner layer composed of 
covalently linked-peptidoglycan (PG), arabinogalactan (AG) and mycolic acid (MA), 
which are highly hydrophobic and forms a lipid barrier around the mycobacterial cell, 
thus affecting mycobacterial cells’ permeability and staining properties (Brennan & 
Nikaido, 1995; Draper, 1998; Todar, 2011). The outer layer consists of free lipids 
and proteins and some non-covalently associated glycolipids (GPLs) such as 
lipoarabinomannan (LAM), phospholipids including phosphatidylinositol 
mannosides (PIMs) and other GPLs specific to mycobacteria. LAM is known to play 
a major role in contributing virulence properties of mycobacterial disease (Chatterjee, 
1997). 
M. tuberculosis is known as an obligate aerobe, where it grows optimally in 
the well-aerated upper portion of the lungs (Todar, 2011). However, it is also a 
facultative intracellular parasite, which resides in human macrophages as its primary 
habitat, by the transmission of airborne particles (Talaro & Chess, 2011; Todar, 
2011). M. tuberculosis has a long generation time of 15 - 20 hours and is highly 
resistant to drying such that the organism could survive for eight months in fine 
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aerosol particles (Talaro & Chess, 2011; Todar, 2011). On the other hand, it does not 
live only in human habitats as there is also evidence of M. tuberculosis being found 
in wastewater (Hartsman et al., 2006). M. tuberculosis is highly pathogenic and has a 
very low infectious dose, which often intensifies the infection process (Kelly et al., 
1996). 
 
2.2.4 Pathophysiology of tuberculosis 
 Tuberculosis is transmitted via airborne particles known as droplets nuclei 
(WHO, 2010). These droplets are produced when pulmonary TB patients cough, 
sneeze, shout, speak or spit. Transmission of TB bacteria is highly dependent on the 
concentration of infectious airborne droplets, exposure duration, and physical 
condition of the exposed individual and environmental factors (Malaysia Health 
Management and Disease Control, 2012). 
 These droplets enter the airway when inhaled and are trapped in the upper 
parts of the airways by mucus-secreting goblet cells, which are then removed from 
the body (Frieden et al., 2003). However, some bacteria in the droplets can bypass 
this barrier and reach the alveoli, whereby they are instantly engulfed by 
macrophages (ATSCDCP, 2000; Frieden et al., 2003). Phagocytosis by macrophages 
triggers a chain of events that results in the successful control of the infection, which 
is soon followed by latent infection that may progress into an active disease later on. 
This phenomenon is known as primary progressive TB (ATSCDCP, 2000). The 
subsequent outcome is determined by the strength of the host immune system and 
the virulence of the invading mycobacteria (van Crevel et al., 2002; Guyot-Revol    
et al., 2006). 
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 The mycobacterial cells continue to proliferate slowly inside the 
macrophages (ATSCDCP, 2000). Macrophages continue to produce proteolytic 
enzymes and cytokines in an attempt to digest the mycobacterial cells                    
(van Crevel et al., 2002). T-lymphocyte is then stimulated by these cytokines and 
form lesions of granulomas around the M. tuberculosis cells (Rosenkrands et al., 
2002; van Crevel et al., 2002). A microenvironment is created in a granuloma that 
limits the proliferation and transmission of the mycobacteria (Frieden et al., 2003; 
Nicod, 2007). Macrophages are killed in this microenvironment and produce solid 
necrosis in the lesion. However, these mycobacterial cells are able to adapt to the 
condition and survive. The environment changes into caseous necrosis, where O2 
levels and nutrient levels are at extremely low concentrations, associated with a low 
pH. Growth of these bacilli are restricted and enter dormant stage (Dheda et al., 
2005).  
 The lesions will undergo fibrosis and calcification, which will contain all the 
bacilli inside these healed, dormant lesions in individuals with adequate immune 
system (Dheda et al., 2005). Lesions in individuals with weak immune system or 
immunodeficient patients will undergo liquefaction, where the internal contents of 
the lesions including mycobacteria, flow out and enter bronchus and nearby blood 
vessels (Dheda et al., 2005). The individual is now known to have primary 
progressive TB and is likely to infect other people (Li et al., 2002; Frieden et al., 
2003; Dheda et al., 2005). 
 
2.2.5 Diagnosis of tuberculosis 
The most commonly used method in TB diagnosis is the Mantoux skin test 
(WHO, 2003). This tuberculin screening test (TST) is the first practical diagnostic 
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test introduced by von Pirquet in 1909 (Goldstein, 2002). It is carried out by 
injections into the skin of patients. This intracutaneous injection is administered as 
Mantoux test for clinical screening and analysis. A volume of 0.1 mL of purified 
protein derivative (PPD) solution is injected into the patient’s arm and a wheal 
formation could be observed after two to three days. The diameter of the induration 
that transversed the long axis of forearm is measured after 48 hours using a 
specialized ruler (Goldstein, 2002). The strength of this test is that repeating 
tuberculin skin testing on a tuberculin–negative patients who have no infection 
history of M. tuberculosis would not induce a TST-false-positive reaction (Dacso, 
1990). 
In some cases, the reactivity of human body towards TST disappears with 
time. TST will be administered to boost reaction of body to future TST 
administration (Menzies, 1999). Two step tests are utilized to avoid misinterpretation 
of the booster as an infection. A TST will be repeated after one to three weeks if the 
first TST shows a negative result. Two step tests are common for individuals such as 
health care workers who have not taken a test in the last 12 months but will undergo 
regular testing in the future (Thompson et al., 1979). TST also works for latent TB 
infection (ATSCDCP, 2000). 
Traditionally, it is believed that chest radiographic expression of primary TB 
are mediastinal lymph node enlargement, lower lobe lesions, and pleural effusions, 
whereas, upper lobe lesions, cavitation, and fibrosis express the post-primary forms 
(Lee et al., 1993; Lee et al., 2000; Jeong & Lee, 2008). However, it is actually 
relatively hard to distinguish between primary and post-primary TB using a chest 
radiograph, since their features might overlap. Furthermore, confirming the diagnosis 
is much more crucial than determining the sub-type as it allows appropriate clinical 
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management (Burrill et al., 2007). It is also important to note that chest radiographs 
are not definitive test of PTB and sputum smear test and isolation of the etiologic 
organism have to be carried out (Burrill et al., 2007). Sputum smear test has been the 
primary method to identify PTB infection in most low and middle-income countries 
as it is an easy-to-carry-out, cost-efficient and rapid technique (Hopewell et al., 
2006). The downside of this technique is that it fails to detect the presence of the 
mycobacteria with a bacteria load of less than 10,000 organism per mL of sputum 
sample (Desikan, 2013). It is also ineffective in detecting EPTB, paediatric TB and 
in TB cases with HIV infection (Perkins, 2000). 
The definitive TB diagnosis requires successful and proper isolation of TB 
pathogen from appropriate specimens (Fillioil et al., 2003). Specimens are collected 
depending on the site of the disease such as lungs, pus, urine, stool and body fluids. 
BACTEC 460 (Becton Dickinson Instrument System, Sparks, MD) is developed as 
an automatic radiometric system for the identification of mycobacteria (Garg et al., 
2003). However, the price of the BACTEC system and the cost of radioactive waste 
disposals is high and unaffordable for most healthcare centres.  
Drug-susceptibility test should also be carried out upon successful isolation 
of the mycobacteria (Heifets & Cangelosi, 1999). These test are usually carried out 
using first-line and second-line anti-TB drugs on agar plates and requires around two 
weeks to obtain definitive results. 
Recent findings have introduced new TB diagnostic methods such as 
serological test, usage of polymerase chain reaction (PCR) and nucleic acid 
amplification tests. Serological test is based on the detection of antibodies to M. 
tuberculosis antigens, thus, it is able to give simple and rapid diagnosis at a very low 
cost. However, serological test results are often inaccurate and imprecise for clinical 
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diagnostics, and thus, limiting their effectiveness (Steingart et al., 2012). On the 
other hand, although PCR and nucleic acid amplifications tests are able to give a 
more accurate result, their usage remained limited among low-income countries as 
these tests required highly trained personnel for handling and incur high cost 
(Steingart et al., 2012). 
 
2.2.6 Treatment and prevention of tuberculosis 
According to WHO, an ideal anti-TB drug should not only be cheap and of 
low toxicity, but it also must possess the ability to contribute a strong bactericidal 
activity and sterilizing activity towards metabolically active and semi-dormant 
bacilli (WHO, 1991). The drug must also be able to inhibit the development of 
resistant bacilli. However, no known chemotherapeutic agent contains all of the 
mentioned properties, whereby, its anti-tubercular activity is significant enough to 
act on its own (WHO, 1991). Thus, a six-month chemotherapy treatment composed 
of at least four first-line anti-TB drugs has been established, such as isoniazid, 
rifampicin, pyrazinamide and ethambutol (WHO, 2010). All four drugs are given to 
the TB patients for the first two months of the intensive phase treatment while 
rifampicin and isoniazid are continued for the next four months of continuation 
phase. The dosing frequency of these drugs varies according to the patient’s 
condition. The recommended doses of each first-line anti-TB drugs for adults are as 
shown in Table 2.1 (WHO, 2010). 
Treatment of new TB patients with high level of isoniazid resistance would 
not be effective even with the six-month chemotherapy (Menzies et al., 2009). In this 
case, patients may receive isoniazid, rifampicin, ethambutol and pyrazinamide 
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during the intensive phase of treatment and isoniazid, rifampicin and ethambutol as 
alternative therapeutical regimen in the continuation phase (WHO, 2010).  
 MDR-TB is extremely difficult to be treated. The recommended regimen for 
MDR-TB is to use at least four second-line anti-TB drugs, such as capreomycin, 
kanamycin and amikacin, together with pyranzinamide for 20 months (WHO, 2003). 
However, second-line drugs are less effective and more toxic to the human body. A 
shorter regimen for treating MDR-TB has been established recently, where 
gatiofloxacin, clofazimine, ethambutol and pyrazinamide are administered 
throughout the nine month treatment period, together with high dose of isoniazid, 
prothionamide and kanamycin for the first four months of intensive phase            
(Van Deun et al., 2010). However, patients who show good progress during the 
treatment period, might have a higher risk in acquiring drug resistance and relapse 
with TB in the future (WHO, 2015b). 
WHO has aimed to reduce the number of deaths caused by TB by 95 % and a 
90 % reduction in TB cases by year 2035 (WHO, 2015b). WHO is currently 
formulating a comprehensive approach in improving TB diagnostic, treatment and 
prevention. Future TB vaccine research would be focusing on prevention of infection, 
prevention of disease and prevention of recurrence (Tuberculosis Vaccine 
Development, 2015). The currently used Bacille Calmette-Guérin (BCG) vaccine 
was first administered onto human by Albert Calmette and Camille Guérin in 1921 
(Behr & Small, 1999). It is the most widely used vaccine until today (Tuberculosis 
Vaccine Development, 2015). Studies showed that BCG vaccine can reduce TB risk 
by 50 % but the period of protection could not be calculated   (Colditz et al, 1994). 
On the other hand, despite the introduction of the newly developed DNA-subunit or   
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Table 2.1. Recommended doses of first-line anti-tuberculosis drugs for adults. 
(WHO, 2010) 
 
Drug 
Recommended dose 
Daily 3 times per week 
Dose and range  
(mg/kg body 
weight) 
Maximum 
(mg) 
Dose and range  
(mg/kg body 
weight) 
Daily 
maximum (mg) 
Isoniazid 5 (4-6) 300 10 (8-12) 900 
Rifampicin 10 (8-12) 600 10 (8-12) 600 
Pyrazinamide 25 (20-30) - 35 (30-40) - 
Ethambutol 15 (15-20) - 30 (25-35) - 
Streptomycin 15 (12-18) - 15 (12-18) 1000 
 
Notes: 
1. Daily (rather than three times weekly) intensive-phase dosing may help to prevent 
acquired drug resistance in TB patients starting treatment with isoniazid resistance. 
2. Acceptable alternative provided that the patient is receiving directly observed therapy and 
is not living with HIV or living in an HIV-prevalent setting. 
3. WHO no longer recommends omission of ethambutol during the intensive phase of 
treatment for patients with non-cavitary, smear-negative PTB or EPTB who are known to 
be HIV-negative. In tuberculous meningitis, ethambutol should be replaced by 
streptomycin. 
4. Patients aged over 60 years may not be able to tolerate more than 500–750 mg daily, so 
some guidelines recommend reduction of the dose to 10 mg/kg per day in patients in this 
age group. Patients weighing less than 50 kg may not tolerate doses above 500–750 mg 
daily. 
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protein vaccine and attenuated M. tuberculosis vaccine, their effectiveness on TB 
vaccination still requires many improvements and improvising (Martin et al., 2006). 
Another major problem in TB vaccine development is due to the lack of correlation 
between immunological data and duration of vaccine protection (Tuberculosis 
Vaccine Development, 2015). 
 
2.3 Challenges in latent tuberculosis management 
Tuberculosis pathogenesis is commonly caused by an exogenous (recently 
acquired) infection or occasionally an endogenous (reactivation of latent TB) 
infection (van Rie et al., 1999; Lillebaek et al., 2002). Most people develop latent 
TB when they are infected with dormant M. tuberculosis (Tufariello et al., 2003). 
Latent TB is generally non-infectious. However, patient with latent TB infection has 
a chance of  5 - 15 % of developing active pulmonary TB disease and become highly 
infectious (WHO, 2015b). 
Latent TB remains a big problem in TB disease management due to the fact 
that latent bacilli had proven to be difficult to kill (Karakousis et al., 2008). This is 
because conventional drugs for M. tuberculosis can only attack and kill them in their 
active replication state but not in their latent phase (Sharbati-Tehrani, 2005). In 2010, 
it was estimated that around 10 to 15 million individuals in the United States are 
affected with such latent infection (Shiloh & Champion, 2010).  
Initial infection normally does not cause disease as most of the tubercle 
bacilli are being cleared away by the body’s immune system (Murray et al., 1991).   
However, some tubercle bacilli can enter as asymptotic, inactive cells and remain in 
latent phase for decades before a relapse occurs (Murray et al., 1990).  Some patients 
show calcified (healed) lesions in their lungs, which is believed to contain dormant  
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TB bacilli, with the possibilities to develop into a clinical, active TB later in life and  
the pathology pattern is often very similar to active TB (Kassa et al., 2012). 
Under normal conditions, peptide complex and major histocompability 
complex (MHC) class II antigens are formed by processing the mycobacterial 
antigens in phagosomes (Ramachandra et al., 2001). However, in a latent TB 
infection, the mycobacterial cells are capable of inhibiting the antigen presentation 
process in human body immune response, causing some M. tuberculosis cells not 
eliminated even after being engulfed by phagosomes (Ramachandra et al., 2001). It 
was found that the level of peptide complex in phagosome containing live bacilli is 
higher than those containing dead mycobacterial cells, suggesting that live 
mycobacteria could attenuate or retard the MHC class II antigen processing 
mechanism and thus, preventing maturation of phagosomes (Noss et al., 2001). 
Studies have shown that the interference starts almost immediately after the 
mycobacteria are being engulfed (Noss et al., 2001). This suggests that                    
M. tuberculosis could alter the MHC class II antigen processing pathway during its 
infection (Noss et al., 2001). 
 Study on latent TB is vital as the mycobacteria could remain hidden in the 
body without generating any symptoms on the patient and could be reactivated any 
time (Parrish et al., 1998).  The risk of being infected by TB would increase if the 
person is co-infected with HIV (Flynn & Chan, 2001). As latent TB has the tendency 
to develop into a MDR-TB, an effective cure against them remains a big health 
problem (Karakousis et al., 2008). Therefore, it is vital to establish laboratory 
models that could allow us to study this disease to stop its spread. 
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2.4 STRATEGIES FOR LATENT TUBERCULOSIS RESEARCH 
2.4.1 Target organisms 
 Ideally, the target organism should be the etiologic agent, M. tuberculosis, 
itself. However, it is extremely slow growing and highly pathogenic, making 
research on these mycobacterial cells to be extremely dangerous, time consuming 
and expensive (Forrellad et al., 2013). Thus, it is wiser to utilize surrogate 
mycobacteria organisms for research, particularly, in laboratories without biosafety 
level three facility. 
Surrogate organism is defined as organism that is utilized to study the fate of 
a pathogen in a specific environment (Sinclair et al., 2012). Surrogate mycobacteria 
species, such as M. smegmatis and M. fortuitum are classified under the same genus 
as M. tuberculosis and are widely used in molecular analysis of M. tuberculosis. The 
surrogate organisms selected in this research have faster growth rate and low 
virulence compared to M. tuberculosis (Rao et al., 2001). Most surrogate 
mycobacteria are environmental opportunist, with no evidence of spread of disease 
in human is found (Wallace, 1994, Bryant et al., 2013). 
 
Mycobacterium smegmatis 
The advantage of using M. smegmatis as a surrogate organism is that it is safe 
to handle because there are no cases of M. smegmatis infection reported since its 
discovery in 1884 (Pierre-Audigier et al., 1997). Despite a clear understanding of its 
genome sequence, very little is known about its growth-controlling-mechanism 
(Draper, 1998). M. smegmatis is considered as a rapid grower among Mycobacterium 
species due to its relatively short generation time of 3 to 6 hours (Klann et al., 1998). 
This short generation time largely shortens the duration on research as compared to 
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M. tuberculosis. M. smegmatis shows close resemblance to M. tuberculosis in its 
response to anaerobiosis and substrate deprivation, which they share a number of 
genes required in adaption to stress condition (O’Toole et al., 2003). On the other 
hand, M. smegmatis is also able to oxidize carbon monoxide under aerobic condition, 
like M. tuberculosis (King, 2003). 
 
Mycobacterium fortuitum 
Although M. fortuitum is classified as a rapid grower among Mycobacterium 
species, it is actually a slow growing organism because it requires 3 to 5 days to 
form liquid culture with high turbidity or colonies on solid medium at 37 ºC     
(Smith, 1976). This low growth rate also means that the mycobacteria die off very 
slowly under natural conditions, a phenomenon similar to M. tuberculosis          
(Soini & Musser, 2001). Unlike M. tuberculosis, it is an environmental opportunistic 
mycobacteria (Wallace, 1994). However, it is always mistaken as a saprophyte 
(Wallace, 1994). It is reported that M. fortuitum is responsible for most diseases 
caused by rapidly growing mycobacteria especially infections that incurred due to 
cardiac bypass surgery (Wallace et al., 1989; Wallace, 1994). However, no proof of 
any person-to-person spread had been discovered, making them safe to work with 
(Wolinsky, 1979).  
 
Mycobacterium kansasii 
Mycobacterium kansasii is known as a slow growing bacteria, like               
M. tuberculosis. It grows well within 32 ºC to 42 ºC, but could not grow at 
temperature above 42 ºC (Falkinham, 1996). It is an opportunist pathogen, which 
could only cause lymphadenitis and various infections to skin, respiratory system 
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and connective tissue in individuals with weak immune system (Wolinsky, 1979). 
Like M. tuberculosis, M. kansasii is reported to be able to adapt to in vitro growth 
under microaerophilic condition with ease. Up to today, no evidence of human-to-
human transmission has been found for M. kansasii infection and thus, become a 
safer option in M. tuberculosis research (Powell & Steadham, 1981).  
 
Mycobacterium tuberculosis H37Ra 
Serial passage of generations of M. tuberculosis H37 through media culture 
with different pHs had gave rise to two forms of mycobacteria strains: the virulent   
M. tuberculosis H37Rv and the attenuated M. tuberculosis H37Ra (Steenkeen et al., 
1934). M. tuberculosis H37Ra is an attenuated tubercle bacillus closely related to the 
virulent type strain M. tuberculosis H37Rv (Brosch et al., 1999). M. tuberculosis 
H37Ra is the best surrogate for the virulent H37Rv strain in primary screening assay, 
as it has less biosafety concerns and lower requirement of biocontainment level 
(Collins & Franzblau, 1997). 
 
2.4.2 In vivo animal models 
Various laboratory in vivo models have been used to help scientists study 
latent TB such as mouse, guinea pig and rabbit models (Tufariello et al., 2003). Each 
model has its own respective advantages over one another. Mouse model, as the 
most commonly used model, has the most economical value and uses easily 
available immunogenic reagents (Orme et al., 1994). Mice are relatively resistant to 
TB development, allowing studies on establishing latent TB infection to be carried 
out easily (Miyazaki et al, 1999). The Cornell mouse model developed by McCune 
in Cornell University in the 1950s is the most accepted mouse model for studying 
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TB dormancy (Miyazaki et al, 1999). The mice are treated with anti-TB drugs such 
as isoniazid and pyrazinamide to kill actively replicating TB bacilli following the 
infection of high dose of M. tuberculosis. However, active infection relapsed in one-
third of the mice after stopping the chemotherapy for three months               
(Miyazaki et al, 1999). Relapse occurs in almost all mice when immunosuppressant 
therapy is applied to the mice. Surprisingly, the bacilli recovered from these TB 
relapsed mice are acid fast and completely susceptible to isoniazid and pyrazinamide, 
suggesting that dormant bacilli do not develop a resistance to drugs at the genetic 
level but only phenotypically resistance to drugs in their dormant state             
(Gupta & Katoch, 2005). Although mouse model plays a large role in understanding 
TB latency and reactivation, it lacks consistency and stability, and do not resemble 
host immunity-induced latent TB infection as the mouse does not develop a well-
formed granuloma and lacks the formation of caseous necrotic centre as in humans        
(Phyu et al., 1998). 
Latent infection could not be established in a guinea pig model due to the 
animals’ high susceptibility to M. tuberculosis (Ordway et al., 2008). A recent study 
with reproducible results proved the existence of dormant TB bacilli in the lung 
lesions of guinea pigs, but the particular strain, M. tuberculosis 18b, which is a 
streptomycin-auxotrophic mutant, is available only to certain laboratories      
(Lenaerts et al., 2007). The most important part of this model is that, it could 
develop a strong delayed-type hypersensitivity response, which closely resembles 
human system (Dannenberg & Collins, 2001). The main limitations with this model 
is the unavailability of immunological agent and higher cost compared to mouse 
model (Gupta & Katoch, 2005). 
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Unlike the mouse model, the rabbit model is able to replicate the formation of 
caseous necrosis centre, which represents the clinical condition in humans     
(Converse et al., 1996). Rabbit is utilized for studying latent TB infection due to its 
high resistance to M. tuberculosis, which often causes TB infection to stay dormant 
within the rabbit (Manabe et al., 2008). In their research, the lungs of rabbits were 
infected with the mycobacteria by the aerosol route. Samples were taken from 
infected rabbits’ lung at fixed interval to observe the growth of the mycobacteria. 
Initially, growth of these bacilli are observable at the infection sites. However, no 
growth of bacilli could be observed in these samples after the fifth week of infections. 
Although no bacilli were found after four months of infection, some rabbits develop 
active TB at the sixth month (Manabe et al., 2008). These results have suggested that 
latent TB infection and its reactivation in these rabbits occur in similar fashion with 
humans (Manabe et al., 2008). However, in vivo research using rabbit model have 
been limited due to the lack of available immunological reagents, the extensive space 
and high cost required for breeding rabbits compared to mouse or guinea pig models 
(Gupta & Katoch, 2005). 
 
2.4.3 Laboratory in vitro models 
Carbohydrate, lipids, nitrogen metabolism and oxidative phosphorylation 
have been used to study the metabolism of mycobacteria in in vitro models to further 
understand the physiology of mycobacteria by limiting oxygen supply in order to 
induce latent TB (Wayne & Lin, 1982; Masood, 1985). However, when actively 
growing M. tuberculosis in aerated culture was abruptly transferred to anaerobic 
condition, it died rapidly with a half-life of only 10 hours (Wayne & Lin, 1982). 
Nevertheless, mycobacteria was found to adapt to microaerophillic conditions when 
